Glenmark Africa

Key therapeutic categories

  • Dermatology
  • Gynaecology
  • Respiratory
  • Gastroenterology

We made an entry in the fast evolving and complex market of Africa in 1990 and over the decades we have successfully expanded operations to more than 15 markets in the region with key markets being South Africa, Kenya, Nigeria and Sudan.

We acquired Bouwer Bartlett Pty. Ltd. through our wholly owned Swiss subsidiary, Glenmark Pharmaceuticals SA in December 2005 and increased our local market presence in South Africa, Botswana, Zimbabwe and Namibia.

In the year 2006, we enhanced our existing portfolio by acquiring a range of products from PD Pharmaceuticals as well as in–licensing a range of dermatological products from MZ Pharmaceuticals. These additions helped us immensely and contributed towards our strong presence in the dermatology segment of the region.

The South African subsidiary is the largest subsidiary for us in the Africa region with Glenmark being ranked among the top 50 companies of the country.

Markets The geographies we cater to:

  • Kenya
  • Nigeria
  • Sudan
  • South Africa
  • Tanzania
  • Uganda
  • Ethiopia
  • Egypt
  • Mauritius
  • Zimbabwe and Botswana
  • West Africa
  • Ghana
  • Zambia
  • Malawi